Exploring and validating surrogate endpoints in colorectal cancer

Tomasz Burzykowski, Marc Buyse, Greg Yothers, Junichi Sakamoto, Dan Sargent

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Sargent et al (J Clin Oncol 23: 8664-8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years.

Original languageEnglish (US)
Pages (from-to)54-64
Number of pages11
JournalLifetime Data Analysis
Volume14
Issue number1
DOIs
StatePublished - Mar 2008

Fingerprint

Surrogate Endpoint
Colorectal Cancer
Colorectal Neoplasms
Biomarkers
Disease-Free Survival
Chemotherapy
Adjuvant Chemotherapy
Treatment Effects
Therapeutics
Clinical Trials
Replacement
Cancer
Valid
Predict
Prediction
Neoplasms

Keywords

  • Colorectal cancer
  • Surrogate endpoint
  • Surrogate threshold effect

ASJC Scopus subject areas

  • Applied Mathematics
  • Medicine(all)

Cite this

Burzykowski, T., Buyse, M., Yothers, G., Sakamoto, J., & Sargent, D. (2008). Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Analysis, 14(1), 54-64. https://doi.org/10.1007/s10985-007-9079-4

Exploring and validating surrogate endpoints in colorectal cancer. / Burzykowski, Tomasz; Buyse, Marc; Yothers, Greg; Sakamoto, Junichi; Sargent, Dan.

In: Lifetime Data Analysis, Vol. 14, No. 1, 03.2008, p. 54-64.

Research output: Contribution to journalArticle

Burzykowski, T, Buyse, M, Yothers, G, Sakamoto, J & Sargent, D 2008, 'Exploring and validating surrogate endpoints in colorectal cancer', Lifetime Data Analysis, vol. 14, no. 1, pp. 54-64. https://doi.org/10.1007/s10985-007-9079-4
Burzykowski, Tomasz ; Buyse, Marc ; Yothers, Greg ; Sakamoto, Junichi ; Sargent, Dan. / Exploring and validating surrogate endpoints in colorectal cancer. In: Lifetime Data Analysis. 2008 ; Vol. 14, No. 1. pp. 54-64.
@article{39efaef1de7c48ed84a7bf5a2be2b8d0,
title = "Exploring and validating surrogate endpoints in colorectal cancer",
abstract = "Sargent et al (J Clin Oncol 23: 8664-8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years.",
keywords = "Colorectal cancer, Surrogate endpoint, Surrogate threshold effect",
author = "Tomasz Burzykowski and Marc Buyse and Greg Yothers and Junichi Sakamoto and Dan Sargent",
year = "2008",
month = "3",
doi = "10.1007/s10985-007-9079-4",
language = "English (US)",
volume = "14",
pages = "54--64",
journal = "Lifetime Data Analysis",
issn = "1380-7870",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Exploring and validating surrogate endpoints in colorectal cancer

AU - Burzykowski, Tomasz

AU - Buyse, Marc

AU - Yothers, Greg

AU - Sakamoto, Junichi

AU - Sargent, Dan

PY - 2008/3

Y1 - 2008/3

N2 - Sargent et al (J Clin Oncol 23: 8664-8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years.

AB - Sargent et al (J Clin Oncol 23: 8664-8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years.

KW - Colorectal cancer

KW - Surrogate endpoint

KW - Surrogate threshold effect

UR - http://www.scopus.com/inward/record.url?scp=39149109136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149109136&partnerID=8YFLogxK

U2 - 10.1007/s10985-007-9079-4

DO - 10.1007/s10985-007-9079-4

M3 - Article

C2 - 18205045

AN - SCOPUS:39149109136

VL - 14

SP - 54

EP - 64

JO - Lifetime Data Analysis

JF - Lifetime Data Analysis

SN - 1380-7870

IS - 1

ER -